EJ Gane et al. Gastroenterol 2017; 152: 1366-71. This phase 2, open-label study (n=53) examined the efficacy of ledipasvir plus sofusbuvir for 8 or 12 weeks for Hepatitis C virus (HCV) genotype 2. An SVR was noted in 96% with 12 weeks of treatment and 74% with 8 weeks of treatment. The only patient in the 12 week group without an SVR did not complete treatment. Overall, this study stands in contrast with the ION-3 study which showed that 8 weeks of therapy led to an SVR of 94% among genotype 1. Thus, this study is consistent with ledpasvir having more potency against genotye 1 and the need for a 12 week course with genotype 2 HCV.
IM Jacobson et al. Gastroenterol 2017; 152: 1372-82. This retrospective study examined 402 patients with HCV genotypes 1, 4 or 6 with Child-Pugh A compensated cirrhosis who were treated with Elbasvir/Grazoprevir. Key finding: SVR12 was 98% and 89% for treatment-naive and treatment-experienced patients after 12 weeks of therapy. The authors noted that baseline tests were done to look for resistance-associated substitutions (RASs). They recommend: “GT1a patients with RASs require extension of therapy to 16 weeks and addition of ribavirin.”
IM Jacobson et al. Gastroenterol 2017; 152: 1378-87. This AGA clinical practice update makes recommendations for patients have achieved an SVR after HCV therapy. These recommendations are mainly expert opinion given the recent advent of newer treatments for HCV and lack of data regarding long-term outcomes after these treatments. Recommendations from authors:
- SVR should be confirmed by undetectable HCV RNA at 12 weeks after treatment regimen
- Reconfirmation of SVR at 48 weeks after treatment is recommended.
- Surveillance for HCC with liver imaging ± AFP should be pursued twice annually for an indefinite duration in all patients with stage 3 fibrosis or liver cirrhosis post-SVR. Surveillance is “not recommended for patients with stages 0-2 fibrosis post SVR.”
- Endoscopic screening for varices is recommended for all patients with cirrhosis, independent of SVR. Repeat screening should be considered if no varices or small varices are noted 2-3 years later. If there are still no varices at 2-3 years, no further endoscopic screening is recommended.
Related blog posts:
- HCV Guidelines
- Hepatitis C -Can We Really Accomplish Widespread Screening?
- Word of Caution with New Hepatitis C Medications | gutsandgrowth
- Keeping Track of HCV Trials -Three More
- It is Hard to Keep Track…